Document 0909
 DOCN  M9540909
 TI    Thalidomide and the immune system. 4. Down-regulation of the CD26
       receptor, probably involved in the binding of HIV components to T cells
       in primates.
 DT    9504
 AU    Neubert R; Helge H; Neubert D; University Medical Center, Free
       University Berlin, Germany.
 SO    Life Sci. 1994 Dec 30;56(6):407-20. Unique Identifier : AIDSLINE
       MED/95131657
 AB    Thalidomide (Thd) is capable of down-regulating the CD26 receptor on
       CD4+ lymphocytes after treatment of healthy volunteers. Similar effects
       are observed when marmosets (Callithrix jacchus) are treated with Thd.
       The Ta1 epitope of the CD26 receptor has recently been shown to bind the
       HIV-1 Tat trans-activating protein, and CD26 has also been suggested to
       be a coreceptor for the binding of the V3 loop of the gp120 HIV envelope
       protein. This might provide a hint for possible therapeutic
       interventions.
 DE    Animal  Antibodies, Monoclonal/DIAGNOSTIC USE  Antigens, CD26/*DRUG
       EFFECTS  Callithrix  CD8-Positive T-Lymphocytes/DRUG EFFECTS
       Down-Regulation (Physiology)/DRUG EFFECTS  Flow Cytometry  Human  Male
       Receptors, HIV/*DRUG EFFECTS  Reference Values  Support, Non-U.S. Gov't
       T-Lymphocytes/*DRUG EFFECTS/IMMUNOLOGY  Thalidomide/*PHARMACOLOGY
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).